Lung Cancer pp 39-51 | Cite as

Cellular Predictive Factors of Drug Resistance in Non-Small Cell Lung Carcinomas

  • Manfred Volm
  • Reet Koomägi
  • Werner Rittgen
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 75)


Resistance to chemotherapy is a major source of failure in cancer treatment. A large number of cancers are intrinsically resistant to cytostatic agents; others initially respond to treatment, but subsequently develop a resistance to the drugs being used. Of the human solid malignancies, small cell lung carcinomas (SCLCs) are among the most chemosensitive and radiosensitive tumors, with most of them responding to initial therapy. However, the majority not only will recur but will remain largely refractory to further treatment. Most non-small cell lung carcinomas (NSCLCs) are primarily resistant to therapy; it is rare to obtain a complete response.


Vascular Endothelial Growth Factor Proliferate Cell Nuclear Antigen Apoptotic Index Dihydrofolate Reductase Small Cell Lung Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bradley, G., Juranka, P. F., and Ling, V. (1988) Mechanisms of multidrug resistance. Biochim. Biophys. Acta 948, 87–128.PubMedGoogle Scholar
  2. 2.
    Volm, M. and Mattern, J. (1996) Resistance mechanisms and their regulation in lung cancer. Crit. Rev. Oncogenesis 7, 227–244.PubMedGoogle Scholar
  3. 3.
    Valeriote, F. and van Putten, L. (1975) Proliferation-dependant cytotoxicity of anticancer agents. A review. Cancer Res. 3, 2619–2630.Google Scholar
  4. 4.
    Cordon-Cardo, C. (1995) Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia (review). Am. J. Pathol. 147, 545–560.PubMedGoogle Scholar
  5. 5.
    Hickman, J. A. (1996) Apoptosis and chemotherapy resistance. Eur. J. Cancer 6, 921–926.CrossRefGoogle Scholar
  6. 6.
    Giaccia, A. J. (1996) Hypoxic stress proteins: Survival of the fittest. Sem. Rad. Oncol. 6, 46–58.CrossRefGoogle Scholar
  7. 7.
    Scanlon, K. J., Jiao, L., Wang, W., Tone, T., Rossi, J. J., and Kashani-Sabet, M (1991) Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl. Acad. Sci. USA 88, 10591–10595.PubMedCrossRefGoogle Scholar
  8. 8.
    Volm, M., Wayss, K., Kaufmann, M., and Mattern, J. (1979). Pretherapeutic detection of tumour resistance and the results of tumor chemotherapy. Eur. J. Cancer 15, 938–993.Google Scholar
  9. 9.
    Group for sensitivity testing of tumors (KSST) (1981) In vitro short-term test to determine the resistance of human tumors to chemotherapy. Cancer 48, 2127–2135.CrossRefGoogle Scholar
  10. 10.
    Volm, M. and Rittgen, W. (2000) Cellular predictive factors for the drug response of lung cancer. Anticancer Res. 20, 3449–3458.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2003

Authors and Affiliations

  • Manfred Volm
    • 1
  • Reet Koomägi
    • 1
  • Werner Rittgen
    • 1
  1. 1.Department of Oncological Diagnostics and Therapy, Central Unit of BiostatisticsGerman Cancer Research CenterHeidelbergGermany

Personalised recommendations